Use of tacrolimus 0.1% and pimecrolimus 1% for treatment of flares of moderate to severe atopic dermatitis and for maintenance and prevention in patients with a high frequency of atopic dermatitis exacerbations, i.e. 4 or more times per year.1 They are particularly useful for the eyelids and face where skin atrophy is a risk. Neither product causes skin atrophy. They both need approval by a Dermatologist or Pediatrician.
Tacrolimus 0.1% is currently indicated for patients aged 16 and over while pimecrolimus 1% cream is indicated from age 3 months. However, off-label (OL) use of tacrolimus down to 3 months has been effective without significant side effects. OL use includes vitiligo in hair bearing areas. If no improvement after 8 weeks stop. Other OL use is psoriasis on the face.